These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14728853)

  • 1. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
    Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Hoffman MA; Blessing JA; Nuñez ER
    Gynecol Oncol; 2001 Jun; 81(3):433-5. PubMed ID: 11371134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Selvaggi L; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Marforio G; Ballardini M; Lombardi AV; Sorio R; Tumolo S; Costa B; Magni G; Perrone F; Favalli G;
    Oncology; 2006; 71(5-6):320-6. PubMed ID: 17878745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
    Hoffman MA; Blessing JA; Morgan M
    Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study.
    Plaxe SC; Blessing JA; Bookman MA; Creasman WT
    Gynecol Oncol; 2002 Jan; 84(1):32-5. PubMed ID: 11748972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
    Lee HP; Seo SS; Ryu SY; Kim JH; Bang YJ; Park SY; Nam JH; Kang SB; Lee KH; Song YS
    Gynecol Oncol; 2008 Jun; 109(3):359-63. PubMed ID: 18405948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
    Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
    Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
    Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
    Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
    Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer.
    Satthapong D; Tangjitgamol S; Manusirivithaya S; Pataradool K
    J Med Assoc Thai; 2007 Mar; 90(3):411-9. PubMed ID: 17427513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T; Inbar M; Menczer J; Grisaru D; Glezerman M; Safra T
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma.
    Zhang MM; Chan JK; Husain A; Guo HY; Teng NN
    Gynecol Oncol; 2007 Apr; 105(1):194-8. PubMed ID: 17257661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.